Amoxycillin-Clavulanate Vs Azithromycin for Respiratory Exacerbations of Bronchiectasis in Children - A Multi-Centre Double Blind Non-Inferiority Randomised Controlled Trial
File version
Author(s)
Grimwood, K
Byrnes, CA
Masters, IB
Marchant, J
Morris, P
Ware, R
Van Asperen, P
O'Grady, K
Torzillo, P
McCallum, G
Champion, A
Buntain, H
Mackay, I
Sloots, TP
Ungerer, J
Binks, M
Chang, AB
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
San Diego, CA
License
Abstract
Based on limited available data, amoxycillin‐clavulanate is the current recommended first‐line empirical oral‐antibiotic treatment for non‐severe bronchiectasis exacerbations in children.
Journal Title
Conference Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Book Title
Edition
Volume
197
Issue
Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
Respiratory System
General & Internal Medicine
Persistent link to this record
Citation
Goyal, V; Grimwood, K; Byrnes, CA; Masters, IB; Marchant, J; Morris, P; Ware, R; Van Asperen, P; O'Grady, K; Torzillo, P; McCallum, G; Champion, A; Buntain, H; Mackay, I; et al., AB, Amoxycillin-Clavulanate Vs Azithromycin for Respiratory Exacerbations of Bronchiectasis in Children - A Multi-Centre Double Blind Non-Inferiority Randomised Controlled Trial, American Journal of Respiratory and Critical Care Medicine, 2018, 197